Role of Polygenic Risk Score in Cancer Precision Medicine of Non-European Populations: A Systematic Review.
Howard Lopes Ribeiro JuniorLázaro Antônio Campanha NovaesJosé Guilherme DatorreDaniel Antunes MorenoRui Manuel Vieira ReisPublished in: Current oncology (Toronto, Ont.) (2022)
The development of new screening methods and diagnostic tests for traits, common diseases, and cancer is linked to the advent of precision genomic medicine, in which health care is individually adjusted based on a person's lifestyle, environmental influences, and genetic variants. Based on genome-wide association study (GWAS) analysis, rapid and continuing progress in the discovery of relevant single nucleotide polymorphisms (SNPs) for traits or complex diseases has increased interest in the potential application of genetic risk models for routine health practice. The polygenic risk score (PRS) estimates an individual's genetic risk of a trait or disease, calculated by employing a weighted sum of allele counts combined with non-genetic variables. However, 98.38% of PRS records held in public databases relate to the European population. Therefore, PRSs for multiethnic populations are urgently needed. We performed a systematic review to discuss the role of polygenic risk scores in advancing precision medicine for different cancer types in multiethnic non-European populations.
Keyphrases
- genome wide
- healthcare
- papillary thyroid
- squamous cell
- genome wide association study
- copy number
- dna methylation
- mental health
- primary care
- public health
- metabolic syndrome
- physical activity
- magnetic resonance
- cardiovascular disease
- squamous cell carcinoma
- small molecule
- childhood cancer
- emergency department
- type diabetes
- health information
- artificial intelligence
- machine learning
- young adults
- weight loss
- computed tomography
- peripheral blood
- clinical practice
- quantum dots
- electronic health record
- single cell
- network analysis
- adverse drug
- health insurance